Department of Surgery, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.
Eur J Cancer Care (Engl). 2009 Sep;18(5):438-46. doi: 10.1111/j.1365-2354.2008.00951.x. Epub 2009 Jul 20.
Despite recent advances in the surgical and medical treatment of breast cancer, the number of patients dying from the disease is still high. In addition to improvements of early diagnosis and treatment, the overall mortality of breast cancer could be reduced by means of preventive intervention in both women with particularly normal and with high risk. Preventing the potentially deadly disease is presumably more effective than treatment, for life quality issues as well as for the economic perspective. Chemoprevention though is still a research field with results from large prevention trials being discussed controversially. For women with a defined increased risk for breast cancer, tamoxifen may be a choice for chemoprevention, balancing carefully benefits against risks. With promising results in adjuvant settings, aromatase inhibitors may deliver better prevention treatment options in the future, nevertheless, more research is needed to reliably predict risk on an individual basis in the future.
尽管乳腺癌的外科和医学治疗最近取得了进展，但死于该病的患者人数仍然居高不下。除了改进早期诊断和治疗外，通过对具有特殊正常风险和高风险的女性进行预防性干预，还可以降低乳腺癌的总体死亡率。预防潜在的致命疾病的效果可能比治疗要好，无论是从生活质量还是经济角度来看都是如此。尽管化学预防仍然是一个研究领域，但大型预防试验的结果仍存在争议。对于乳腺癌风险增加的女性，他莫昔芬可能是一种化学预防选择，需要仔细权衡利弊。在辅助治疗中取得了有希望的结果，芳香酶抑制剂可能在未来提供更好的预防治疗选择，但仍需要更多的研究来可靠地预测未来个体的风险。
